Getting Past the “Pharma Bro"; How Smaller Biotechs Continue to Strive for the Well-Being of Patients
NEW YORK, April 5, 2016 /PRNewswire/ --
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company reports the Company’s CEO was featured in an interview in the April issue of PharmaVOICE magazine.
PharmaVOICE magazine, reaching more than 41,000 BPA-qualified life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry.
CEO, Denis Corin talks to PharmaVOICE magazine about Martin Shkreli’s actions, drug prices and how he and his company are approaching the issues facing biotech innovators now and in the future.
Excerpt:
PV: Martin Shkreli’s decision to increase the price of an inexpensive drug from $13.50 to $750 created a media uproar, reigniting negative attitudes toward the life-sciences industry. Is there anything positive that can come from this?
Corin: It’s created a talking point, and it’s provided more focus on the pharmaceutical industry and biotechnology to a degree. His approach and his attitude is just not consistent with the majority of people in pharma development and certainly not true of the younger, smaller biotech companies that are truly the innovators and the driving force behind a lot of new drug creation. This attitude is not reflective of the way many of us do things or the reasons why we do what we do.
Quite candidly, in the smaller-cap biotech space, companies are being run on shoestring budgets, and we’re out there every day raising dollars wherever we can to develop these assets.
The way Shkreli’s positioned this - gouging people on this one particular drug - is not representative of what’s going on in the biotech innovation space. Every biotech CEO has to have some kind of philanthropy or philanthropic outlook on life when it comes to what he or she is doing. We have to be doing it for the ultimate good of the patients and their families and if we can do that, all things will fall into place and the company will do well. There will be ample profit for the shareholders and enough money to feed back into innovation and drug development.
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.
Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435
